HC Wainwright Reiterates “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Friday,Benzinga reports.

A number of other research analysts have also commented on ESPR. The Goldman Sachs Group began coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Cantor Fitzgerald began coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $7.30.

Esperion Therapeutics Price Performance

ESPR stock opened at $2.34 on Friday. The stock has a market cap of $461.07 million, a price-to-earnings ratio of -3.66 and a beta of 1.01. The company has a fifty day moving average price of $2.46 and a two-hundred day moving average price of $2.18. Esperion Therapeutics has a one year low of $1.58 and a one year high of $3.94.

Hedge Funds Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. BOKF NA bought a new position in Esperion Therapeutics in the 2nd quarter valued at approximately $26,000. Traphagen Investment Advisors LLC acquired a new stake in Esperion Therapeutics in the third quarter valued at $27,000. Xponance Inc. bought a new position in Esperion Therapeutics during the 2nd quarter worth $28,000. National Bank of Canada FI lifted its holdings in Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 10,225 shares during the period. Finally, Versor Investments LP acquired a new stake in shares of Esperion Therapeutics in the third quarter valued at about $44,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.